Methylation analysis of SHOX2 and RASSF1A in bronchoalveolar lavage fluid for early lung cancer diagnosis

Annals of Diagnostic Pathology

Volumn 27, Issue , 2017, Pages 57-61

  Ren, Minpu ^a   Wang, Chunhua ^a,b   Sheng, Danli ^a   Shi, Yaoyao ^a   Jin, Mei ^a   Xu, Songxiao ^a  

^a ZHEJIANG UNIVERSITY   (China)

^b Second Hospital of Jiaxing   (China)

Author keywords

Diagnosis; Lung Cancer; Methylation; RASSF1A; SHOX2

Indexed keywords

ADOLESCENT; ADULT; AGED; ARTICLE; BENIGN RESPIRATORY TRACT TUMOR; CONTROLLED STUDY; CORRELATION ANALYSIS; CYTOPATHOLOGY; FEMALE; GENE; HUMAN; HUMAN CELL; LARGE CELL LUNG CARCINOMA; LUNG ADENOCARCINOMA; LUNG ADENOSQUAMOUS CARCINOMA; LUNG CANCER; LUNG CARCINOMA; LUNG LAVAGE; MAJOR CLINICAL STUDY; MALE; METHYLATION; PRIORITY JOURNAL; RAS ASSOCIATION DOMAIN FAMILY PROTEIN 1A GENE; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SANGER SEQUENCING; SHORT STATURE HOMEOBOX GENE TWO; SMALL CELL LUNG CANCER; SQUAMOUS CELL LUNG CARCINOMA; BRONCHOALVEOLAR LAVAGE FLUID; CYTOLOGY; DNA METHYLATION; GENETICS; LUNG TUMOR; METABOLISM; MIDDLE AGED; NON SMALL CELL LUNG CANCER; PROMOTER REGION; VERY ELDERLY;

HOMEODOMAIN PROTEIN; RASSF1 PROTEIN, HUMAN; SHOX2 PROTEIN, HUMAN; TUMOR SUPPRESSOR PROTEIN;

ADULT; AGED; AGED, 80 AND OVER; BRONCHOALVEOLAR LAVAGE FLUID; CARCINOMA, NON-SMALL-CELL LUNG; DNA METHYLATION; FEMALE; HOMEODOMAIN PROTEINS; HUMANS; LUNG NEOPLASMS; MALE; MIDDLE AGED; PROMOTER REGIONS, GENETIC; TUMOR SUPPRESSOR PROTEINS;

EID: 85012239733     PISSN: 10929134     EISSN: 15328198     Source Type: Journal    
DOI: 10.1016/j.anndiagpath.2017.01.007     Document Type: Article

References (33)

1. [1] McGuire, S., World Cancer Report, Geneva, Switzerland: World Health Organization, International Agency for Research on Cancer. Adv Nutr 2016, 2015, 2014, WHO Press, 418–419 7(2).
2. [2] Li, Y., Dai, M., Chen, Y., et al. Estimates of lung cancer mortality at the province level in China. Zhongguo Fei Ai Za Zhi 14:2 (2011), 120–126.
3. [3] Hong, Q.Y., Wu, G.M., Qian, G.S., et al. Prevention and management of lung cancer in China. Cancer 121:Suppl. 17 (2015), 3080–3088.
4. [4] Zahir, S.T., Mirtalebi, M., Survival of patients with lung cancer, Yazd, Iran. Asian Pac J Cancer Prev 13:9 (2012), 4387–4391.
5. [5] Roth, K., Hardie, J.A., Andreassen, A.H., et al. Predictors of diagnostic yield in bronchoscopy: a retrospective cohort study comparing different combinations of sampling techniques. BMC Pulm Med, 8, 2008, 2.
6. [6] Alharbi, K.K., Clinical efficacy and possible applications of genomics in lung cancer. Asian Pac J Cancer Prev 16:5 (2015), 1693–1698.
7. [7] Schreiber, G., McCrory, D.C., Performance characteristics of different modalities for diagnosis of suspected lung cancer: summary of published evidence. Chest 123:Suppl. 1 (2003), 115S–128S.
8. [8] Alharbi, K.K., Clinical efficacy and possible applications of genomics in lung cancer. Asian Pac J Cancer Prev 16:5 (2015), 1693–1698.
9. [9] I H, Cho, J.Y., Lung cancer biomarkers. Adv Clin Chem 72 (2015), 107–170.
10. [10] Jones, P.A., Baylin, S.B., The fundamental role of epigenetic events in cancer. Nat Rev Genet 3:6 (2002), 415–428.
11. [11] Esteller, M., Herman, J.G., Cancer as an epigenetic disease: DNA methylation and chromatin alterations in human tumours. J Pathol 196:1 (2002), 1–7.
12. [12] Esteller, M., Herman, J.G., Cancer as an epigenetic disease: DNA methylation and chromatin alterations in human tumours. J Pathol 196:1 (2002), 1–7.
13. [13] Mehta, A., Dobersch, S., Romero-Olmedo, A.J., Barreto, G., Epigenetics in lung cancer diagnosis and therapy. Cancer Metastasis Rev 34:2 (2015), 229–241.
14. [14] Langevin, S.M., Kratzke, R.A., Kelsey, K.T., Epigenetics of lung cancer. Transl Res 165:1 (2015), 74–90.
15. [15] Darwiche, K., Zarogoulidis, P., Baehner, K., et al. Assessment of SHOX2 methylation in EBUS-TBNA specimen improves accuracy in lung cancer staging. Ann Oncol 24:11 (2013), 2866–2870.
16. [16] Katayama, H., Hiraki, A., Fujiwara, K., et al. Aberrant promoter methylation profile in pleural fluid DNA and clinicopathological factors in patients with non-small cell lung cancer. Asian Pac J Cancer Prev 8:2 (2007), 221–224.
17. [17] Kneip, C., Schmidt, B., Seegebarth, A., et al. SHOX2 DNA methylation is a biomarker for the diagnosis of lung cancer in plasma. J Thorac Oncol 6:10 (2011), 1632–1638.
18. [18] Mikeska, T., Bock, C., Do, H., Dobrovic, A., DNA methylation biomarkers in cancer: progress towards clinical implementation. Expert Rev Mol Diagn 12:5 (2012), 473–487.
19. [19] Feinberg, A.P., Ohlsson, R., Henikoff, S., The epigenetic progenitor origin of human cancer. Nat Rev Genet 7:1 (2006), 21–33.
20. [20] Yu, L., Liu, H., Yan, M., et al. Shox2 is required for chondrocyte proliferation and maturation in proximal limb skeleton. Dev Biol 306:2 (2007), 549–559.
21. [21] Endoh, H., Yatabe, Y., Shimizu, S., et al. RASSF1A gene inactivation in non-small cell lung cancer and its clinical implication. Int J Cancer 106:1 (2003), 45–51.
22. [22] Grote, H.J., Schmiemann, V., Geddert, H., et al. Methylation of RAS association domain family protein 1A as a biomarker of lung cancer. Cancer 108:2 (2006), 129–134.
23. [23] Schmidt, B., Liebenberg, V., Dietrich, D., et al. SHOX2 DNA methylation is a biomarker for the diagnosis of lung cancer based on bronchial aspirates. BMC Cancer, 10, 2010, 600.
24. [24] Nie, K., Jia, Y., Zhang, X., Cell-free circulating tumor DNA in plasma/serum of non-small cell lung cancer. Tumour Biol 36:1 (2015), 7–19.
25. [25] Yu, L., Liu, H., Yan, M., et al. Shox2 is required for chondrocyte proliferation and maturation in proximal limb skeleton. Dev Biol 306:2 (2007), 549–559.
26. [26] Agathanggelou, A., Cooper, W.N., Latif, F., Role of the Ras-association domain family 1 tumor suppressor gene in human cancers. Cancer Res 65:9 (2005), 3497–3508.
27. [27] Dammann, R., Li, C., Yoon, J.H., et al. Epigenetic inactivation of a RAS association domain family protein from the lung tumour suppressor locus 3p21.3. Nat Genet 25:3 (2000), 315–319.
28. [28] Dietrich, D., Kneip, C., Raji, O., et al. Performance evaluation of the DNA methylation biomarker SHOX2 for the aid in diagnosis of lung cancer based on the analysis of bronchial aspirates. Int J Oncol 40:3 (2012), 825–832.
29. [29] Schreiber, G., McCrory, D.C., Performance characteristics of different modalities for diagnosis of suspected lung cancer: summary of published evidence. Chest 123:1 Suppl (2003), 115S–128S.
30. [30] Tomizawa, Y., Iijima, H., Nomoto, T., et al. Clinicopathological significance of aberrant methylation of RARbeta2 at 3p24, RASSF1A at 3p21.3, and FHIT at 3p14.2 in patients with non-small cell lung cancer. Lung Cancer 46:3 (2004), 305–312.
31. [31] Li, W., Deng, J., Tang, J.X., Combined effects methylation of FHIT, RASSF1A and RARbeta genes on non-small cell lung cancer in the Chinese population. Asian Pac J Cancer Prev 15:13 (2014), 5233–5237.
32. [32] Topaloglu, O., Hoque, M.O., Tokumaru, Y., et al. Detection of promoter hypermethylation of multiple genes in the tumor and bronchoalveolar lavage of patients with lung cancer. Clin Cancer Res 10:7 (2004), 2284–2288.
33. [33] Schmiemann, V., Böcking, A., Kazimirek, M., et al. Methylation assay for the diagnosis of lung cancer on bronchial aspirates: a cohort study. Clin Cancer Res 11:21 (2005), 7728–7734.